NASDAQ:ALXO

ALX Oncology News Headlines

$63.77
-8.41 (-11.65 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$63.50
Now: $63.77
$71.93
50-Day Range
$62.84
MA: $74.52
$87.68
52-Week Range
$28.01
Now: $63.77
$117.45
Volume199,900 shs
Average Volume244,004 shs
Market Capitalization$2.56 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Headlines

ALX Oncology (NASDAQ ALXO) News Headlines Today

SourceHeadline
UBS Group Begins Coverage on ALX Oncology (NASDAQ:ALXO)UBS Group Begins Coverage on ALX Oncology (NASDAQ:ALXO)
marketbeat.com - April 6 at 8:16 AM
ALX Oncology (NASDAQ:ALXO) Shares Gap Down to $72.18ALX Oncology (NASDAQ:ALXO) Shares Gap Down to $72.18
americanbankingnews.com - April 9 at 11:02 AM
ALX Oncology (NASDAQ:ALXO) Sees Large Volume IncreaseALX Oncology (NASDAQ:ALXO) Sees Large Volume Increase
americanbankingnews.com - April 8 at 11:50 AM
Have Insiders Been Buying ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares?Have Insiders Been Buying ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares?
nasdaq.com - April 6 at 5:05 PM
ALX Oncology (NASDAQ:ALXO) Now Covered by Analysts at UBS GroupALX Oncology (NASDAQ:ALXO) Now Covered by Analysts at UBS Group
americanbankingnews.com - April 6 at 8:52 AM
ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148ALX Oncology Strengthens IP Portfolio; Announces End of Post-Grant Review Period for Issued U.S. Patent Covering ALX148
finance.yahoo.com - April 5 at 7:39 AM
Alx Oncology Holdings Inc (ALXO) President and CEO Jaume Pons Sold $1.1 million of SharesAlx Oncology Holdings Inc (ALXO) President and CEO Jaume Pons Sold $1.1 million of Shares
finance.yahoo.com - March 24 at 10:51 PM
ALX Oncology (NASDAQ:ALXO) Shares Gap Up to $63.07ALX Oncology (NASDAQ:ALXO) Shares Gap Up to $63.07
americanbankingnews.com - March 22 at 11:30 AM
ALX Oncology (NASDAQ:ALXO) Announces  Earnings ResultsALX Oncology (NASDAQ:ALXO) Announces Earnings Results
americanbankingnews.com - March 19 at 1:09 PM
ALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming MilestonesALX Oncology Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development and Operational Highlights and Upcoming Milestones
finance.yahoo.com - March 18 at 9:20 PM
ALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of DirectorsALX Oncology Announces Appointment of Sophia Randolph, M.D., Ph.D., to Board of Directors
finance.yahoo.com - March 15 at 11:56 AM
ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer ImmunotherapeuticsALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
finance.yahoo.com - March 4 at 5:37 PM
Why Earnings Season Could Be Great for ALX Oncology (ALXO)Why Earnings Season Could Be Great for ALX Oncology (ALXO)
finance.yahoo.com - March 3 at 2:16 PM
ALX Oncology to Participate at H.C. Wainwright Global Life Sciences ConferenceALX Oncology to Participate at H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - March 2 at 9:01 AM
Have Insiders Been Buying ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares This Year?Have Insiders Been Buying ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares This Year?
finance.yahoo.com - January 16 at 8:24 AM
IPO Lockup Expiration Alert: ALX Oncology Holdings Inc. (ALXO) IPO Lockup Expiration Alert: ALX Oncology Holdings Inc. (ALXO)
markets.businessinsider.com - January 12 at 11:59 PM
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2021
finance.yahoo.com - January 11 at 7:33 AM
ALX Oncology to Present at 39th Annual J.P. Morgan Healthcare ConferenceALX Oncology to Present at 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 8:28 AM
ALX Oncology Added to the NASDAQ Biotechnology IndexALX Oncology Added to the NASDAQ Biotechnology Index
finance.yahoo.com - December 17 at 7:54 AM
ALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesALX Oncology Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - December 14 at 8:38 PM
Is ALXO A Good Stock To Buy Now?Is ALXO A Good Stock To Buy Now?
finance.yahoo.com - December 11 at 11:16 PM
ALX Oncology Announces Pricing of Upsized Public Offering of Common StockALX Oncology Announces Pricing of Upsized Public Offering of Common Stock
finance.yahoo.com - December 10 at 12:11 AM
ALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin LymphomaALX Oncology Announces Updated Data from ASPEN-01, the Ongoing Phase 1b Study of ALX148, Showing Robust, Durable Activity in Patients with Non-Hodgkin Lymphoma
finance.yahoo.com - December 7 at 5:18 PM
ALX Oncology Announces Proposed Public Offering of Common StockALX Oncology Announces Proposed Public Offering of Common Stock
finance.yahoo.com - December 7 at 5:18 PM
ALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer StudiesALX Oncology Announces Updates on Planned ALX148 Phase 2 Head and Neck Cancer Studies
finance.yahoo.com - December 7 at 8:29 AM
ALX Oncology Announces December 2020 Virtual Investor Conference ParticipationALX Oncology Announces December 2020 Virtual Investor Conference Participation
markets.businessinsider.com - November 24 at 7:21 AM
ALX Oncology Holdings (ALXO) Presents New ALX148 Data from the Phase 1b Gastric/GEJ Expansion Cohort in ASPEN-01 - SlideshowALX Oncology Holdings (ALXO) Presents New ALX148 Data from the Phase 1b Gastric/GEJ Expansion Cohort in ASPEN-01 - Slideshow
seekingalpha.com - November 22 at 6:44 PM
ALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational HighlightsALX Oncology Reports Third Quarter 2020 Financial Results and Provides Clinical Development and Operational Highlights
finance.yahoo.com - November 12 at 6:39 PM
ALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid TumorsALX Oncology Announces New Data from ASPEN-01, the Phase 1b Study of ALX148, Showing Promising Initial Clinical Responses in Patients with Advanced Solid Tumors
finance.yahoo.com - November 9 at 12:23 PM
ALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual MeetingALX Oncology to Present ALX148 Clinical Data at the 62nd American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 5 at 9:20 AM
ALX Oncology Announces November 2020 Virtual Investor Conference ParticipationALX Oncology Announces November 2020 Virtual Investor Conference Participation
finance.yahoo.com - November 2 at 8:11 AM
Dosing underway for ALX Oncologys ALX148 in mid-stage blood cancer studyDosing underway for ALX Oncology's ALX148 in mid-stage blood cancer study
seekingalpha.com - October 28 at 9:22 AM
ALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic SyndromeALX Oncology Announces First Patient Dosed in ASPEN-02, a Phase 1/2 Study of ALX148 in Combination with Azacitidine in Patients with Myelodysplastic Syndrome
finance.yahoo.com - October 28 at 9:22 AM
ALX Oncology Names Leading Oncology Experts to Scientific Advisory BoardALX Oncology Names Leading Oncology Experts to Scientific Advisory Board
markets.businessinsider.com - October 6 at 7:52 AM
ALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck CancerALX Oncology to Collaborate with Merck on Phase 2 Immuno-Oncology Studies Evaluating ALX148, Targeting CD47, in Combination with KEYTRUDA® (pembrolizumab) in Patients with Head & Neck Cancer
finance.yahoo.com - September 22 at 3:41 PM
ALX Oncology to join the Rusell 2000 and Rusell 3000 indexesALX Oncology to join the Rusell 2000 and Rusell 3000 indexes
seekingalpha.com - September 17 at 9:57 AM
ALX Oncology Added to Russell 2000® and 3000® IndexesALX Oncology Added to Russell 2000® and 3000® Indexes
finance.yahoo.com - September 17 at 9:57 AM
ALX Oncology Announces Participation at Upcoming Investor ConferencesALX Oncology Announces Participation at Upcoming Investor Conferences
finance.yahoo.com - September 8 at 9:14 AM
ALX Oncology misses on revenueALX Oncology misses on revenue
seekingalpha.com - August 27 at 8:27 PM
ALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical HighlightsALX Oncology Reports Second Quarter 2020 Financial Results and Provides Operational and Clinical Highlights
finance.yahoo.com - August 27 at 8:27 PM
ALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional SharesALX Oncology Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - August 11 at 1:28 PM
This page was last updated on 4/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.